


ETCTN Trials by Disease/Treatment Area: Genitourinary Cancer



NOTE ▼ Limited trial; not open ETCTN-wide.

## ETCTN Genitourinary Cancer Trials (Open as of 3/10/2025)

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10144</b>	II	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
<b>10301</b>	I/II	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
<b>10466</b>	II	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
<b>10483</b>	Ib	Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations
<b>10487</b>	II	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation
<b>10603</b>	II	Phase II Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
<b>10636</b>	I	Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer